New York, NY -- (SBWIRE) -- 12/10/2018 -- Top Five Companies Account for 35% Share of the Overall Hormone Replacement Therapy Market
The hormone replacement therapy market is a fragmented landscape with presence of few tier one companies and upcoming players. Top five companies involved in the hormone replacement therapy formulations account for a significant share of the overall hormone replacement therapy market. Top 5 players – Novo Nordisk, Pfizer Inc., Janssen NV (a Johnson & Johnson company), Novartis AG and Bayer AG collectively – collectively account for 35 percent revenue share of the hormone replacement therapy market from on the global front.
Tier 1 hormone replacement therapy companies are focused on carrying out clinical trials for new product development (NPD). Moreover, these companies are adopting vertical, horizontal and backward integration in a bid to achieve rapid expansion and pace in technological development.
In addition, tier 1 hormone replacement therapy companies are forming alliances to co-develop and commercialize hormone replacement therapy drugs. For instance, Pfizer Inc., and Merck KGaA have formed a strategic alliance to develop avelumab (BAVENCIO) to manage hypothyroidism and other thyroid disorders.
Agreement between FDA and NASEM to Impact Hormone Replacement Therapy Market Growth
Food and Drug Administration (FDA) has signed an agreement with NASEM (National Academies of Science, Engineering & Medicine) and is carrying out expanded agreements with University of Maryland and Johns Hopkins University Centers for Regulatory Science and Innovation. Main focus behind this initiative was to conduct research and inform consumers regarding compounded drugs.
NASEM is examining the utility of treating individuals with compounded BHRT (Bioidentical Hormone Replacement Therapy) products. Compounded Bioidentical hormone replacement therapy products such as testosterone and progesterone are used instead of FDA approved hormone replacement therapy drugs as BHRT drugs are considered more safe and natural for patients. This factor is likely to impact the clinical trials of new hormone replacement therapy products in turn challenging the growth of hormone replacement therapy market.
Request For Sample Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=2224
Use of Low Cost Generic Versions of Hormone Replacement Therapy Drugs – An Upcoming Trend
Affordability has always remained a major challenge for any pharmaceutical drug or formulation. Moreover, insufficient healthcare reimbursements have resulted in individuals opting for cheaper drugs with unclear drug effectiveness. This prompted manufactures of hormone replacement therapy drugs to produce generic versions of the formulations in a bid to bridge the gap between purchasing power of people and hormone replacement therapy drug pricing. Companies developing generic hormone replacement therapy drugs are also acquiring FDA approvals, which is direct inference apropos to drug effectiveness. For instance, Teva pharmaceuticals has introduced generic version of Estrace cream and estradiol vaginal cream in 2018. The trend is expected to auger well for the overall growth of the hormone replacement therapy market.
Rising Prevalence of Osteoporosis to Influence Hormone Replacement Therapy Demand
Growing life expectancy is closely associated with degeneration that further translates into osteoporotic fractures. In addition, this condition further results in an increase in gap between spine bones during menopause with diminishing estrogen levels. According to the International Osteoporosis Foundation, osteoporosis causes over 8.9 million fractures annually on the global front and is likely to grow in the coming years. Rising prevalence of osteoporosis among women is expected to trigger the demand for hormone replacement therapy.
Hormone Replacement Therapy Associated with Reduced Dementia – Key Growth Propellant
Hormone replacement therapy can protect memory which is required to carry out short-term cognitive tasks after menopausal stress. Estrogen-only hormone replacement therapy can facilitate lower stress levels without impacting memory. In addition, hormone replacement therapy also reduces possibilities of both vascular dementia and Alzheimer's disease.
Combination Hormone Replacement Therapy Associated with Cancer – Key Growth Deterrent
Use of hormone replacement therapy can lead to cancerous cell development. The use of combination hormone replacement therapy (combination of progesterone and estrogen) can increase the risk of breast cancer by 75 percent even if used for a short timeframe. According to the U.S Women's Health Initiative, the use of combination hormone replacement therapy comes with the risk of development of several cancers including ovarian and uterus cancers. This aspect is expected to confine the growth in adoption of hormone replacement therapy in the forthcoming years. Other hormone replacement therapy related disorders such as stroke, cardiac disorders and blood clots are further expected to negatively impact the growth of the hormone replacement therapy market.
Competitive Landscape
The report on hormone replacement therapy market offers intelligence on key participants in the hormone replacement therapy market. The key companies involved in the formulation of hormone replacement therapy products are thoroughly assessed and profiled in the report. Various facets of competition including SWOT analysis, product portfolio analysis, drug developments and innovations, strategies and key financials are covered. Key companies profiled in the report include Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals, Mylan N.V and Pfizer Inc.
Major companies in the hormone replacement therapy market are concentrating on expanding their current product portfolio. New hormone replacement therapy formulations being the core focus, companies are carrying out trials and gain FDA approvals. For instance, Novartis AG's research and development department delivered 6 critical FDA breakthrough therapy designations and 16 submissions in 2017. In May 2017, Novartis AG announced U.S. FDA's approval for its hormone replacement therapy tablets for hormone receptor positive and metastatic breast cancer treatment in postmenopausal women.
In February 2018, Novo Nordisk A/S concluded main phase of REAL 1 – the pivotal phase 3 trial along with somapacitan, a long-acting growth hormone to treat adults with growth hormone deficiency.
Teva Pharmaceuticals Industries Ltd. introduced Vagifem in 2017 for the treatment of atrophic vaginitis. In January 2018, the company launched Estrace cream to treat moderate and severe symptoms of vaginal and vulgar atrophy occurring due to menopause. Likewise, Mylan N.V expanded its US portfolio in the women's healthcare range with U.S. FDA approval for Estradiol Vaginal Cream to treat vaginal atrophy.
Private equity firms are focused on acquiring emerging participants that are involved in drug delivery systems in the hormone replacement therapy space. For instance, Riverside Company has acquired DoseLogix in a bid to provide innovative dosing dispensers for ensuring accurate dosing medications of hormone replacement therapy and other conditions.
Request Brochure of this Report-
https://www.factmr.com/connectus/sample?flag=RC&rep_id=2224
Definition
Hormone replacement therapy, also referred to as menopausal hormone therapy, is used to treat various symptoms related to menopause among women. Hormone replacement therapy replaces hormones that are low in level as women near menopause. There are various types of hormone replacement therapy such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy.
About the Report
The report on hormone replacement therapy market provides incisive insights on all aspects influencing growth in demand for hormone replacement therapy worldwide. The report provides a thorough analysis on demand of hormone replacement therapy across key regions in the globe along with sales of various hormone replacement therapy products.
Key drivers, challenges, trends and opportunities shaping the growth of the hormone replacement therapy market are also covered in the hormone replacement therapy market report. The hormone replacement therapy market report provides historical data assessment on use of hormone replacement therapy, current hormone replacement therapy scenario and future demand of hormone replacement therapy. The forecast projections provided cover a timeline of 10 years (2018-2028).
Market Structure
The hormone replacement therapy market is segmented in detail to cover every angle of the hormone replacement therapy space. The hormone replacement therapy market has been segmented on the basis of product type, by dosage form, by indication, by distribution channel and by region.
Various hormone replacement therapy products such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy is covered. By dosage form, hormone replacement therapy market is segmented into tablets, patches, injections, implants and creams. By indications, hormone replacement therapy market is categorized into menopause, osteoporosis, thyroid and growth hormone deficiency. By distribution channel, it is segmented by hospital pharmacies, clinics, retail pharmacies and online pharmacies.
The hormone replacement therapy market is assessed across key regions such as North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Middle East and Africa (MEA) and Japan.
Additional Questions Answered
Apart from key findings mentioned above, the hormone replacement therapy market report also answers additional questions such as:
Which is the most attractive regional market for hormone replacement therapy?
Which dosage form is largely preferred for using hormone replacement therapy worldwide?
Due to which indication is the hormone replacement therapy market is witnessing a significant upswing in demand?
Which country in the APEJ region accounts for a higher market share in the APEJ hormone replacement therapy?
Which is the most lucrative hormone replacement therapy distribution channel?
Research Methodology
The hormone replacement therapy market is drafted using a unique research methodology comprising of a combination of secondary and primary research methodologies. The data gleaned from primary and secondary research is assessed along with information from external sources. All the statistics are compiled using triangulation method to gain highly accurate projections on hormone replacement therapy market.
Report Overview at https://www.factmr.com/report/2224/hormone-replacement-therapy-market
About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Read Industry News at- www.industrynewsanalysis.com/